JP2023508357A5 - - Google Patents
Info
- Publication number
- JP2023508357A5 JP2023508357A5 JP2022538706A JP2022538706A JP2023508357A5 JP 2023508357 A5 JP2023508357 A5 JP 2023508357A5 JP 2022538706 A JP2022538706 A JP 2022538706A JP 2022538706 A JP2022538706 A JP 2022538706A JP 2023508357 A5 JP2023508357 A5 JP 2023508357A5
- Authority
- JP
- Japan
- Prior art keywords
- cdk
- cyclin
- administering
- inhibitor
- estrogen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952695P | 2019-12-23 | 2019-12-23 | |
| US62/952,695 | 2019-12-23 | ||
| PCT/US2020/066798 WO2021133886A1 (en) | 2019-12-23 | 2020-12-23 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508357A JP2023508357A (ja) | 2023-03-02 |
| JP2023508357A5 true JP2023508357A5 (https=) | 2024-02-01 |
Family
ID=76575087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538706A Pending JP2023508357A (ja) | 2019-12-23 | 2020-12-23 | エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11642342B2 (https=) |
| EP (1) | EP4081518A4 (https=) |
| JP (1) | JP2023508357A (https=) |
| CN (1) | CN116234803A (https=) |
| CA (1) | CA3161892A1 (https=) |
| WO (1) | WO2021133886A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220348595A1 (en) * | 2021-04-09 | 2022-11-03 | Endotarget Inc. | Compounds and methods for the targeted degradation of estrogen receptors |
| KR20240053589A (ko) * | 2021-07-30 | 2024-04-24 | 하이노바 파마슈티컬스 인코포레이티드 | 이중 기능성 키메라 헤테로 고리 화합물 및 이의 안드로겐 수용체 분해제로서의 용도 |
| WO2023102379A1 (en) * | 2021-11-30 | 2023-06-08 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Combination therapy for cancer treatment |
| EP4446324A4 (en) * | 2021-12-08 | 2026-05-06 | Gluetacs Therapeutics Shanghai Co Ltd | Ligand compounds for e3 ubiquitin ligase, protein degraders developed on basis of ligand compounds, and uses thereof |
| WO2023116835A1 (zh) * | 2021-12-24 | 2023-06-29 | 苏州开拓药业股份有限公司 | 一种具有酰亚胺骨架的多蛋白降解剂 |
| CN117229286A (zh) * | 2022-06-14 | 2023-12-15 | 海创药业股份有限公司 | 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途 |
| US20260000676A1 (en) * | 2022-07-12 | 2026-01-01 | The Regents Of The University Of Michigan | Chroman derivatives as estrogen receptor degraders |
| CN115724836B (zh) * | 2022-11-24 | 2025-07-04 | 北京大学 | 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物 |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
| CN116751186B (zh) * | 2022-12-23 | 2024-10-18 | 南京知和医药科技有限公司 | 一种雌激素受体调节剂的制备及其用途 |
| CN119258223A (zh) * | 2023-07-06 | 2025-01-07 | 海创药业股份有限公司 | 一种降解雌激素受体的联合用药物及其用途 |
| US20250381179A1 (en) | 2024-05-22 | 2025-12-18 | Accutar Biotechnology Inc. | Chroman-based compounds for treating cancer |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010021710A1 (en) | 1996-10-28 | 2001-09-13 | Poul Jacobsen | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| TW593256B (en) | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| JP2001306582A (ja) | 2000-04-20 | 2001-11-02 | Ge Plastics Japan Ltd | 成型品情報の検索システム |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| JP2005524630A (ja) | 2002-01-14 | 2005-08-18 | ノルディック・ビオサイエンス・エー／エス | エストロゲン受容体を介する軟骨破壊の抑制 |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| PL2305221T3 (pl) | 2003-12-01 | 2015-11-30 | Kudos Pharm Ltd | Inhibitory naprawy uszkodzeń DNA w leczeniu raka |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| EA201001030A1 (ru) | 2007-12-19 | 2011-02-28 | Амген Инк. | Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| CA2737400C (en) | 2008-10-07 | 2016-11-22 | Astrazeneca Uk Limited | Pharmaceutical formulation 514 |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| EP2558092B1 (en) | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| CN102584687A (zh) | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
| WO2013097773A1 (en) | 2011-12-30 | 2013-07-04 | Centaurus Biopharma Co., Ltd. | Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators |
| CA2906157C (en) | 2013-03-15 | 2022-05-17 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| CN108495618B (zh) * | 2016-07-12 | 2019-08-16 | 冰洲石生物科技公司 | 新的化合物及其用途 |
| BR112019011200B1 (pt) * | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| AU2018282901A1 (en) * | 2017-06-12 | 2020-01-16 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2019133864A1 (en) | 2017-12-29 | 2019-07-04 | Accutar Biotechnology | DUAL INHIBITORS OF PARP1 and CDK |
| WO2019196812A1 (zh) | 2018-04-09 | 2019-10-17 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| US11667621B2 (en) | 2018-06-11 | 2023-06-06 | Stevens Institute Of Technology | Antiestrogen compounds |
| US20220016102A1 (en) | 2018-11-21 | 2022-01-20 | Shanghaitech University | Er protein regulators and use thereof |
| SG11202105256QA (en) * | 2018-11-21 | 2021-06-29 | Accutar Biotechnology Inc | Novel compounds having estrogen receptor alpha degradation activity and uses thereof |
| CN113614076A (zh) * | 2019-01-03 | 2021-11-05 | 密执安大学评议会 | 雌激素受体蛋白降解剂 |
| KR20220054347A (ko) * | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| EP3835298B1 (en) * | 2019-12-12 | 2024-06-26 | Accutar Biotechnology Inc. | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof |
-
2020
- 2020-12-23 JP JP2022538706A patent/JP2023508357A/ja active Pending
- 2020-12-23 CA CA3161892A patent/CA3161892A1/en active Pending
- 2020-12-23 WO PCT/US2020/066798 patent/WO2021133886A1/en not_active Ceased
- 2020-12-23 EP EP20905920.3A patent/EP4081518A4/en active Pending
- 2020-12-23 CN CN202080097414.4A patent/CN116234803A/zh active Pending
-
2021
- 2021-01-04 US US17/140,664 patent/US11642342B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508357A5 (https=) | ||
| JP2025510572A5 (https=) | ||
| JP2019059760A5 (https=) | ||
| EP4079373A4 (en) | THERAPEUTIC ULTRASOUND GENERATING DEVICE AND HANDPIECE FOR ULTRASOUND TREATMENT THEREOF | |
| CN115605510A (zh) | B7h3抗体-依喜替康类似物偶联物及其医药用途 | |
| DK2288413T3 (da) | Terapeutisk anlæg, som kombinerer stråleterapi og termoterapi | |
| ATE511392T1 (de) | Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit | |
| CL2007002358A1 (es) | Sistema de liberacion farmaceutica controlado, oral que comprende uno o mas modificadores de ph, una capa aislante; procedimiento de preparacion; y su uso para el tratamiento de trastornos del sistema nervioso central, sistema afectivo, del sueno y s | |
| WO2008063727A3 (en) | Combination therapy for treatment of viral infections | |
| CN115916778A (zh) | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 | |
| JP2024523003A5 (https=) | ||
| WO2010045417A3 (en) | Combination therapies for the treatment of obesity | |
| CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
| JP2007510667A5 (https=) | ||
| JP2025502266A5 (https=) | ||
| JP2020523354A5 (https=) | ||
| JP2021510343A5 (https=) | ||
| MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
| JO2178B1 (en) | Treatment of emphysema using rar selective retinoid antagonists | |
| CN111867629A (zh) | 抗her2抗体-药物偶联物在治疗癌症中的用途 | |
| JP2003528919A5 (https=) | ||
| AR059838A1 (es) | Formulaciones para dosis estabilizantes de estatina | |
| WO2010045522A3 (en) | Combination therapies for the treatment of obesity | |
| CN116406288A8 (zh) | 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法 | |
| WO2005039497A3 (en) | Methods and compositions comprising thalidomide for treatment of fibromyalgia |